เกี่ยวกับตอนนี้
In this episode of Well Yes, HUM Nutrition co-founder Walter Faulstroh and registered dietitian Sarah Greenfield, RD, dive deep into the GLP-1 weight loss microdosing trend—including semaglutide (Ozempic) and tirzepatide (Mounjaro)—and explore how far people are going to experiment with these drugs in pursuit of better health, body composition, and longevity.
They unpack the science behind GLP-1s, the rise of microdosing culture, and why some wellness enthusiasts are blurring the lines between medicine and lifestyle. Tune in for a real, science-backed discussion about self-experimentation, biohacking, and the future of wellness—plus, when the trend goes too far.
🔍 Topics Covered:
- What GLP-1s like semaglutide and tirzepatide actually do
- The difference between clinical use vs. self-experimentation
- Are we entering the “microdosing everything” era?
- Why injectables aren’t the same as supplements
- The risks and realities behind the hype
🎙️ Well Yes by HUM Nutrition — where science meets wellness trends.
